Grapefruit Juice-Vinblastine Interaction

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

ALEXANDRIA, Virginia-Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).

ALEXANDRIA, Virginia—Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).

The drugs include vinblastine, cyclosporine (Sandimmune, Neoral), losartan (Cozaar, an antihypertension agent), digoxin, and fexofenadine (Allegra, an antihistamine).

This inhibition occurs, the researchers said, because an unknown substance in grapefruit juice activates one of the body’s naturally produced drug efflux mechanisms, P-glycoprotein, located in the intestinal tract. When grapefruit juice interacts with P-glycoprotein, the result is an increased likelihood that certain drugs will be stopped from entering the bloodstream.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.